David Ricks, Eli Lilly CEO (Paulo Nunes dos Santos/Bloomberg via Getty Images)
October 30, 2024 07:16 AM EDTUpdated 08:41 AM
Pharma

Lil­ly miss­es sales fore­cast by $800M, low­ers rev­enue guid­ance for the year 

Kyle LaHucik

Senior Reporter

Eli Lil­ly low­ered the top end of its full-year rev­enue guid­ance by $600 mil­lion on Wednes­day, as its third-quar­ter sales were about $800 mil­lion be­low …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

A start­up backed by No­bel win­ner David Bak­er takes an AI twist on an­ti­bod­ies

Bio­gen signs mol­e­c­u­lar glue deal, rais­es year­ly pro­jec­tions

GSK re­mains ‘very con­fi­dent’ in RSV vac­cine amid com­pe­ti­tion, sales slump

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Sage, Bio­gen won't pur­sue ma­jor de­pres­sion ap­proval for post­par­tum pill

Ax­o­nis snags $115M to test oral drugs for epilep­sy and neu­ro­path­ic pain

A service from the Financial Times